Vensica Medical Advances Needle-Free Overactive Bladder Therapy Into Phase 2 Trial

A LinkedIn post from Vensica Medical reports that the U.S. FDA has cleared the company’s IND application for a Phase 2 clinical trial of ViXe, a needle-free delivery system for botulinum toxin (Xeomin) in overactive bladder. The post indicates the trial will assess the Vibe ultrasound-based platform, which is intended to deliver therapy directly to the bladder wall without needles.

According to the post, the study targets overactive bladder, a condition it notes affects an estimated 33 million adults in the U.S., where current delivery methods may limit patient acceptance. The company suggests that ViXe could improve access to an established therapy by reducing procedural invasiveness.

The post also notes plans to begin patient enrollment across the U.S. and Europe in the coming months, signaling a move into more advanced clinical development for the platform. This progression, if successful, could position Vensica Medical for future value inflection points tied to trial data, partnering potential, or eventual commercialization pathways in urology.

The LinkedIn update attributes the milestone to collaboration with investors and partners including IBF, Merz Pharma (Schweiz) AG, and Laborie. For investors, this level of partner engagement, together with regulatory clearance to advance to Phase 2, may imply growing external validation of the company’s technology and its potential role in the medtech and biotech urology segment.